Abstract
Medical therapy plays a vital role in the neoadjuvant, adjuvant, and palliative management of patients with pancreatic cancer. The medical therapeutic options are largely limited to chemotherapy, and thus consideration for toxicity to balance with intended anticancer effect is requisite. The possible goals of therapy therefore need clear establishment at the outset. Various imaging modalities are an important part of the toolset needed to ascertain the baseline status of a cancer in terms of potential for resection, which will ultimately guide the treatments recommended and sequences of their use. These same imaging modalities remain critical to the assessment of treatment response over time. A considered understanding on how to use these imaging tools is important to ensure that a thorough and focused assessment of a patient’s cancer is achieved, and to tailor management to the individualized goals of the patient. In this chapter, the role of various imaging modalities will be discussed in the context of oncologic management.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- CA 19-9:
-
Carbohydrate antigen 19-9
- CT:
-
Computed tomography
- CTC:
-
Circulating tumor cells
- ctDNA:
-
Circulating tumor DNA
- ESPAC:
-
European Study Group for Pancreatic Cancer
- EUS:
-
Endoscopic ultrasound
- FOLFIRINOX:
-
5-fluorouracil/leucovorin, irinotecan, and oxaliplatin
- mOS:
-
Median overall survival
- PET:
-
Positron emission tomography
References
Amanam I, Chung V. Targeted therapies for pancreatic cancer. Cancers (Basel). 2018;10:E36.
Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, et al. Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34:2541–55.
Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, et al. Locally advanced, unresectable pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34:2654–68.
Cancer stat facts: pancreatic cancer. SEER database. In: https://seer.cancer.gov/statfacts/html/pancreas.html. Accessed 27 May 2019.
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival with nab-paclitaxel plus gemcitabine. N Engl J Med. 2012;369:1691–703.
Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomized, open-label, phase 3 trial. Lancet. 2016;387:545–57.
Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.
Neuhaus P, Riess H, Post S, Gellert K, Ridwelski K, Schramm H, et al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer. J Clin Oncol. 2008;26:LBA4504.
Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–81.
Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomized, phase 3 trial. Lancet. 2017;389:1011–24.
Conroy T, Hammel P, Hebbar M, Abdelghani MB, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406.
Nab-paclitaxel and gemcitabine vs gemcitabine alone as adjuvant therapy for patients with resected pancreatic cancer (the APACT study). In: https://clinicaltrials.gov/ct2/show/NCT01964430. Accessed 10 Jun 2019.
Celgene. Top-line results announced from the international Phase 3 study evaluating adjuvant therapy with ABRAXANE in combination with gemcitabine vs. gemcitabine alone for patients with surgically resected pancreatic cancer [press release] (12 Mar 2019) [cited Jun 10, 2019]. Available from: https://s22.q4cdn.com/728481125/files/doc_news/2019/03/ABRAXANE-Combo-release-Final-Approved2.pdf
Goff SL, Chabot JA. A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer. Cancer J. 2012;18:602–8.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731–9.
Kindler HL, Hammel P, Reni M, Van Cutsem E, Mercade RM, Hall MJ, et al. Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: Phase III POLO trial. J Clin Oncol. 2019;37:suppl:abstr LBA4.
Satoi S, Yamamoto H, Takai S, Tanigawa N, Komemushi A, Yanagimoto H, et al. Clinical impact of multidetector row computed tomography on patients with pancreatic cancer. Pancreas. 2007;34:175–9.
Nordback I, Saaristo R, Piironen A, Sand J. Chest computed tomography in the staging of pancreatic and periampullary carcinoma. Scand J Gastroenterol. 2004;39:81–6.
Motosugi U, Ichikawa T, Morisaka H, Sou H, Muhi A, Kimura K, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging. Radiology. 2011;260:446–53.
Valls C, Andia E, Sanchez A, Fabregat J, Pozuelo O, Quintero JC, et al. Dual phase helical CT of pancreatic adenocarcinoma. Am J Roentgenol. 2002;178:821–6.
Varadarajulu S, Wallace MB. Applications of endoscopic ultrasonography in pancreatic cancer. Cancer Control. 2004;11:15.
Saftoiu A, Vilmann P. Role of endoscopy ultrasound in the diagnosis and staging of pancreatic cancer. J Clin Ultrasound. 2009;37:1.
Fong ZV, Alvino DML, Fernandez Del Castillo C, Mehtsun WT, Pergolini I, Warshaw AL, et al. Reappraisal of staging laparoscopy for patients with pancreatic adenocarcinoma. Ann Sug Oncol. 2017;24:3203.
Robinson SM, Wilson CH, Burt AD, MAnas DM, White SA. Chemotherapy-associated liver injury in patients with colorectal liver metastases. Ann Surg Oncol. 2012;19:4287–99.
Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, et al. Extended preoperative chemotherapy foes not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010;17:2870–6.
NCCN. Pancreatic Adenocarcinoma. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 25 July 2019.
Goonetilleke KS, Siriwadrena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266–70.
Saxena R. In Focus: circulating tumor cells. Available from: Pharmaceurticalintelligence.com. Accessed 18 May 2018.
Varley K. Detecting ctDNA. Available from: uofuhealth.utah.edu. Accessed 18 May 2018.
Liquid biopsy. Available from: healio.com. Accessed 18 May 2018.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Smaglo, B.G. (2021). Imaging Diagnostics in Pancreatic Cancer from the Perspective of an Oncologist. In: Anand, N., Darwin, P. (eds) Imaging Diagnostics in Pancreatic Cancer. Clinical Gastroenterology. Humana, Cham. https://doi.org/10.1007/978-3-030-69940-6_6
Download citation
DOI: https://doi.org/10.1007/978-3-030-69940-6_6
Published:
Publisher Name: Humana, Cham
Print ISBN: 978-3-030-69939-0
Online ISBN: 978-3-030-69940-6
eBook Packages: MedicineMedicine (R0)